Dian-Lei Wang

Dr. Dian-Lei Wang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in PeerJ
Verified
Journal Article
Open access
PDF file
PSPingping Song
Pingping Song
JLJunling Liu
Junling Liu
PHPeng Huang
Peng Huang
ZHZhili Han
Zhili Han
DWDian-Lei Wang
Dian-Lei Wang
NSnianxia sun
nianxia sun
Rhizosphere microorganisms are the main factors affecting the formation of high quality medicinal materials and promoting the accumulation of secondary metabolites. However, the composition, diversity, and function of rhizosphere microbial communities in endangered wild and cultivated Rhizoma Atractylodis Macrocephalae (RAM) and their relationships with active component accumulation have remained unclear. In this study, high-throughput sequencing and correlation analysis were used to study the rhizosphere microbial community diversity (bacteria and fungi) of three RAM species and its correlation with the accumulation of polysaccharides, atractylone, and lactones (I, II, and III). A total of 24 phyla, 46 classes, and 110 genera were detected. The dominant taxa were Proteobacteria, Ascomycota, and Basidiomycota. The microbial communities in both wild and artificially cultivated soil samples were extremely species-rich, but there were some differences in their structure and the relative abundances of microorganism taxa. Meanwhile, the contents of effective components in wild RAM were significantly higher than those in cultivated RAM. Correlation analysis showed that 16 bacterial and 10 fungal genera were positively or negatively correlated with active ingredient accumulation. These results showed that rhizosphere microorganisms could play an important role in component accumulation and might lay a foundation for future research on endangered materials.

23 March 2023 in Phytomedicine
Verified
Journal Article
Closed access
WZWen-Tao Zhu
Wen-Tao Zhu
CLChen-Hui Li
Chen-Hui Li
TDTing-Ting Dai
Ting-Ting Dai
QSQi-Qi Song
Qi-Qi Song
YCYue Chen
Yue Chen
DWDian-Lei Wang
Dian-Lei Wang

1 January 2019 in Drug Delivery
Verified
Journal Article
Open access
WFWei Fang
Wei Fang
ZPZhao Liang Peng
Zhao Liang Peng
YDYa Ji Dai
Ya Ji Dai
DWDian-Lei Wang
Dian-Lei Wang
PHPeng Huang
Peng Huang
HHHe Ping Huang
He Ping Huang
Realgar and (-)-Epigallocatechin-3-gallate (EGCG) are natural medicines that inhibit cancer cell growth, resulting in inhibition of formation and development of tumors. The anticancer effects of realgar and EGCG were greatly improved following formulation as nanoparticles. EGCG has received increased attention as a drug carrier. The aim of this study was to prepare a new nanomedicine, (EGCG-RNPs), in which encapsulated nano-realgar. EGCG-RNPs were prepared by coprecipitation and characterized by transmission electron microscopy (TEM), differential scanning calorimetry (DSC), particle size and zeta potential, X-ray diffraction, Fourier transform infrared spectroscopy (FTIR) and in vitro release. Furthermore, we evaluated the antiproliferative effects of EGCG-RNPs on HL-60 cells in vitro, antitumor effect by intratumoral injection of EGCG-RNPs into solid tumors derived from APL HL-60 cells in vivo. Possible mechanisms were evaluated using uptake and efflux experiments in HL-60 cells. The results showed that the average particle size and zeta potentials of EGCG-RNPs was 200.3 ± 1.23 nm and −46.8 ± 1.31 mV. Controlled release of EGCG-RNPs was sustained and continued up to 72 h in vitro. Compared with nano-realgar and EGCG + RNPs (EGCG and nano-realgar physical mixing), EGCG-RNPs significantly inhibited growth of HL-60 cells. In a solid tumor model, EGCG-RNPs decreased tumor volumes, with an inhibitory rate of 60.18% at a dose of 70 mg · kg−1. The mechanisms of antitumor improvement may correlate with the increased uptake of realgar and prolonged the retention time of realgar in HL-60 cells due to EGCG as a carrier. EGCG-RNPs could enhance anticancer therapeutic efficacy for acute promyelocytic leukemia.

1 February 2020 in Life Sciences
Verified
Journal Article
Closed access
YZYuanyuan Zhou
Yuanyuan Zhou
XXXiaoya Xu
Xiaoya Xu
JWJie Wu
Jie Wu
LXLingling Xu
Lingling Xu
MZMin Zhang
Min Zhang
DWDian-Lei Wang
Dian-Lei Wang

1 December 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
WZWen-Tao Zhu
Wen-Tao Zhu
CLChen-Hui Li
Chen-Hui Li
TDTing-Ting Dai
Ting-Ting Dai
FTFu-Lin Tao
Fu-Lin Tao
MWMeng-Wen Wang
Meng-Wen Wang
DWDian-Lei Wang
Dian-Lei Wang

28 November 2024 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
TDTing-Ting Dai
Ting-Ting Dai
WFWei Fang
Wei Fang
WZWen-Tao Zhu
Wen-Tao Zhu
ZHZhi-Li Han
Zhi-Li Han
NSNian-Xia Sun
Nian-Xia Sun
DWDian-Lei Wang
Dian-Lei Wang